4:05 PM
 | 
May 24, 2018
 |  BC Extra  |  Company News

FDA approves BioMarin's phenylketonuria drug

FDA approved Palynziq pegvaliase-pqpz from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to treat phenylketonuria (PKU) in patients who have uncontrolled blood phenylalanine levels on current treatment.

The company expects to launch the drug by the end...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >